Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous TILs and Aldesleukin in Advanced GIST
NCT07647068Phase 2Not yet recruiting
- Start
- Feb 2027
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in gastrointestinal stromal tumor (GIST). Primary endpoint: Objective Response Rate up to 24 months. Planned start Feb 2027; status: not yet recruiting.
02
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT07647068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07647068.